申请人:Mitsubishi-Tokyo Pharmaceuticals, Inc.
公开号:EP1020449A1
公开(公告)日:2000-07-19
The imidazoline compound represented by the following formula (I):
and its pharmacologically acceptable salts, and the imidazoline compound represented by the following formula (II):
Compound (I) has highly selective antagonistic action on muscarinic M3 receptor subtypes, and especially airway muscarinic M3 receptor subtypes, and is, therefore, particularly useful as a preventive or therapeutic agent for especially, diseases related to muscarinic M3 receptors in chronic obstructive pulmonary disease and asthma, while compound (II) is useful as a production intermediate for compound (I).
以下化学式表示的咪唑啉化合物(I)及其药学上可接受的盐,以及以下化学式表示的咪唑啉化合物(II):化合物(I)对肌胆碱M3受体亚型具有高度选择性的拮抗作用,特别是对气道肌胆碱M3受体亚型具有作用,因此特别适用于慢性阻塞性肺疾病和哮喘等与肌胆碱M3受体相关的疾病的预防或治疗药物,而化合物(II)则可用作化合物(I)的生产中间体。